Raras
Buscar doenças, sintomas, genes...
Síndrome Cushing endógena
ORPHA:641613DOENÇA RARA

Qualquer síndrome de Cushing causada pelo excesso prolongado de cortisol no corpo, que pode ou não depender do hormônio ACTH.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Qualquer síndrome de Cushing causada pelo excesso prolongado de cortisol no corpo, que pode ou não depender do hormônio ACTH.

Pesquisas ativas
2 ensaios
4 total registrados no ClinicalTrials.gov
Publicações científicas
83 artigos
Último publicado: 2026 Apr 8
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
13 sintomas
🧠
Neurológico
12 sintomas
🧬
Pele e cabelo
8 sintomas
🫘
Rins
7 sintomas
🫃
Digestivo
6 sintomas
🦴
Ossos e articulações
6 sintomas

+ 52 sintomas em outras categorias

Características mais comuns

Insônia
Livedo reticularis
Compressão do nervo óptico
Necrose avascular
Defeito do campo visual
Cefaleia
126sintomas
Sem dados (126)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 126 características clínicas mais associadas, ordenadas por frequência.

InsôniaInsomnia
Livedo reticularis
Compressão do nervo ópticoOptic nerve compression
Necrose avascularAvascular necrosis
Defeito do campo visualVisual field defect

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico83PubMed
Últimos 10 anos55publicações
Pico202510 papers
Linha do tempo
2026Hoje · 2026🧪 2007Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

10 genes identificados com associação a esta condição.

GNASProtein ALEXDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May inhibit the adenylyl cyclase-stimulating activity of guanine nucleotide-binding protein G(s) subunit alpha which is produced from the same locus in a different open reading frame

LOCALIZAÇÃO

Cell membraneCell projection, ruffle

VIAS BIOLÓGICAS (10)
G alpha (s) signalling eventsProstacyclin signalling through prostacyclin receptorADORA2B mediated anti-inflammatory cytokines productionGPER1 signalingG alpha (i) signalling events
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
1324.4 TPM
Tireoide
727.3 TPM
Hipotálamo
548.6 TPM
Brain Frontal Cortex BA9
501.2 TPM
Cérebro - Hemisfério cerebelar
474.1 TPM
OUTRAS DOENÇAS (12)
progressive osseous heteroplasiapituitary adenoma 3, multiple typespseudohypoparathyroidism type 1CMcCune-Albright syndrome
HGNC:4392UniProt:P84996
CDH23Cadherin-23Candidate gene tested inTolerante
FUNÇÃO

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells. CDH23 is required for establishing and/or maintaining the proper organization of the stereocilia bundle of hair cells in the cochlea and the vestibule during late embryonic/early postnatal development. It is part of the functional network formed by USH1C, USH1G, CDH23 and MYO7A that mediates mechanotransduction in cochlear hair cells. Required for norma

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Sensory processing of sound by outer hair cells of the cochleaSensory processing of sound by inner hair cells of the cochlea
MECANISMO DE DOENÇA

Usher syndrome 1D

USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness.

OUTRAS DOENÇAS (12)
autosomal recessive nonsyndromic hearing loss 12Usher syndrome type 1Dnonsyndromic genetic hearing lossUsher syndrome
HGNC:13733UniProt:Q9H251
USP48Ubiquitin carboxyl-terminal hydrolase 48Candidate gene tested inAltamente restrito
FUNÇÃO

Deubiquitinase that recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of polyubiquitin precursors as well as that of ubiquitinated proteins (PubMed:16214042, PubMed:34059922). Plays a role in the regulation of NF-kappa-B activation by TNF receptor superfamily via its interactions with RELA and TRAF2. May also play a regulatory role at postsynaptic sites. Plays an important role in cell cycle progression by deubiquitinating Aurora B/AURKB an

LOCALIZAÇÃO

CytoplasmNucleusCell projection, cilium

VIAS BIOLÓGICAS (1)
Ub-specific processing proteases
MECANISMO DE DOENÇA

Deafness, autosomal dominant, 85

A form of non-syndromic, sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA85 is characterized by progressive hearing loss, with onset in childhood or young adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
68.8 TPM
Cérebro - Hemisfério cerebelar
55.8 TPM
Cerebelo
55.3 TPM
Ovário
36.8 TPM
Glândula adrenal
35.5 TPM
OUTRAS DOENÇAS (3)
hearing loss, autosomal dominant 85autosomal dominant nonsyndromic hearing lossCushing disease due to pituitary adenoma
HGNC:18533UniProt:Q86UV5
BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
NR3C1Glucocorticoid receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of ta

LOCALIZAÇÃO

CytoplasmNucleusMitochondrionCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, microtubule organizing center, centrosomeChromosomeNucleus, nucleoplasm

VIAS BIOLÓGICAS (6)
PTK6 ExpressionRegulation of RUNX2 expression and activityRegulation of NPAS4 gene transcriptionFOXO-mediated transcription of oxidative stress, metabolic and neuronal genesSUMOylation of intracellular receptors
MECANISMO DE DOENÇA

Glucocorticoid resistance, generalized

An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.3 TPM
Nervo tibial
34.5 TPM
Tecido adiposo
34.1 TPM
Fibroblastos
33.6 TPM
Artéria tibial
32.7 TPM
OUTRAS DOENÇAS (2)
glucocorticoid resistanceCushing disease due to pituitary adenoma
HGNC:7978UniProt:P04150
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
ATRXTranscriptional regulator ATRXCandidate gene tested inAltamente restrito
FUNÇÃO

Involved in transcriptional regulation and chromatin remodeling. Facilitates DNA replication in multiple cellular environments and is required for efficient replication of a subset of genomic loci. Binds to DNA tandem repeat sequences in both telomeres and euchromatin and in vitro binds DNA quadruplex structures. May help stabilizing G-rich regions into regular chromatin structures by remodeling G4 DNA and incorporating H3.3-containing nucleosomes. Catalytic component of the chromatin remodeling

LOCALIZAÇÃO

NucleusChromosome, telomereNucleus, PML body

VIAS BIOLÓGICAS (2)
Inhibition of DNA recombination at telomereDefective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
MECANISMO DE DOENÇA

Alpha-thalassemia/impaired intellectual development syndrome, X-linked

A disorder characterized by severe psychomotor retardation, facial dysmorphism, urogenital abnormalities, and alpha-thalassemia. An essential phenotypic trait are hemoglobin H erythrocyte inclusions.

OUTRAS DOENÇAS (5)
intellectual disability-hypotonic facies syndrome, X-linked, 1alpha-thalassemia-myelodysplastic syndromealpha thalassemia-X-linked intellectual disability syndromegastric neuroendocrine neoplasm
HGNC:886UniProt:P46100
KDM1ALysine-specific histone demethylase 1ACandidate gene tested inRestrito
FUNÇÃO

Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context (PubMed:15620353, PubMed:15811342, PubMed:16079794, PubMed:16079795, PubMed:16140033, PubMed:16223729, PubMed:27292636). Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed (PubMed:15620353, PubMed:15811342, PubMed:16079794, PubMed:21300290, PubMed:26214369). Acts as a c

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (9)
Regulation of PTEN gene transcriptionPotential therapeutics for SARSHDACs deacetylate histonesNegative Regulation of CDH1 Gene TranscriptionActivated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
MECANISMO DE DOENÇA

Cleft palate, psychomotor retardation, and distinctive facial features

A syndrome characterized by cleft palate, developmental delay, psychomotor retardation, and facial dysmorphic features including a prominent forehead, slightly arched eyebrows, elongated palpebral fissures, a wide nasal bridge, thin lips, and widely spaced teeth. Cleft palate is a congenital fissure of the soft and/or hard palate, due to faulty fusion.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
194.0 TPM
Linfócitos
96.4 TPM
Ovário
86.8 TPM
Útero
79.7 TPM
Cervix Endocervix
79.7 TPM
OUTRAS DOENÇAS (3)
palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndromeCushing syndrome due to macronodular adrenal hyperplasiaACTH-independent macronodular adrenal hyperplasia 3
HGNC:29079UniProt:O60341
ARMC5Armadillo repeat-containing protein 5Candidate gene tested inTolerante
FUNÇÃO

Substrate-recognition component of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes (PubMed:39504960, PubMed:39667934). The BCR(ARMC5) complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the BCR(ARMC5) complex acts by mediating ubiquitination of Pol II subu

LOCALIZAÇÃO

NucleusChromosomeCytoplasm

MECANISMO DE DOENÇA

ACTH-independent macronodular adrenal hyperplasia 2

A form of macronodular adrenal hyperplasia characterized by multiple, bilateral, non-pigmented, benign, adrenocortical nodules. It results in excessive production of cortisol leading to ACTH-independent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.

OUTRAS DOENÇAS (2)
Cushing syndrome due to macronodular adrenal hyperplasiaACTH-independent macronodular adrenal hyperplasia 2
HGNC:25781UniProt:Q96C12
USP8Ubiquitin carboxyl-terminal hydrolase 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation. Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates t

LOCALIZAÇÃO

CytoplasmNucleusEndosome membraneCell membrane

VIAS BIOLÓGICAS (4)
Downregulation of ERBB2:ERBB3 signalingRegulation of FZD by ubiquitinationNegative regulation of MET activityUb-specific processing proteases
MECANISMO DE DOENÇA

Pituitary adenoma 4, ACTH-secreting

A form of pituitary adenoma, a neoplasm of the pituitary gland and one of the most common neuroendocrine tumors. Pituitary adenomas are clinically classified as functional and non-functional tumors, and manifest with a variety of features, including local invasion of surrounding structures and excessive hormone secretion. Functional pituitary adenomas are further classified by the type of hormone they secrete. PITA4 results in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.4 TPM
Linfócitos
9.2 TPM
Nervo tibial
9.1 TPM
Cervix Endocervix
8.7 TPM
Ovário
8.3 TPM
OUTRAS DOENÇAS (2)
Cushing disease due to pituitary adenomaautosomal recessive spastic paraplegia type 59
HGNC:12631UniProt:P40818

Variantes genéticas (ClinVar)

1,778 variantes patogênicas registradas no ClinVar.

🧬 GNAS: NM_016592.5(GNAS):c.138C>A (p.Ala46=) ()
🧬 GNAS: NM_016592.5(GNAS):c.195del (p.Asn66fs) ()
🧬 GNAS: NM_000516.7(GNAS):c.177G>C (p.Gln59His) ()
🧬 GNAS: NM_000516.7(GNAS):c.-2_1del (p.Met1del) ()
🧬 GNAS: NM_000516.7(GNAS):c.516del (p.Ile172fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

76 vias biológicas associadas aos genes desta condição.

GNAS1 GNAS2 GNAS G alpha (s):GTP:SRC dissociates G alpha (s):GTP:SRC catalyzes SRC to p-Y419-SRC G protein alpha (s):GTP binds SRC Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea Ub-specific processing proteases Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations HDACs deacetylate histones HDMs demethylate histones Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Regulation of PTEN gene transcription Estrogen-dependent gene expression NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Negative Regulation of CDH1 Gene Transcription Factors involved in megakaryocyte development and platelet production Downregulation of ERBB2:ERBB3 signaling Regulation of FZD by ubiquitination Negative regulation of MET activity

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 31
2Fase 21
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 4 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Cushing endógena

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

4 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
60 papers (10 anos)
#1

Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.

The Journal of clinical endocrinology and metabolism2026 Mar 14

Endogenous Cushing syndrome (CS) is a rare disorder resulting from chronic exposure to excessive concentrations of cortisol. It is likely underdiagnosed because many clinical signs and symptoms are non-specific and overlap with those of common conditions. Furthermore, biochemical testing to diagnose CS can be complex and challenging, especially in milder cases. CS is characterized by excessive daily cortisol production, but it is also associated with a disrupted circadian rhythm of cortisol secretion. Traditional cortisol monitoring techniques rely on single-time-point measurements or a cumulation of measurements, which are unable to capture the complete daily rhythm of cortisol fluctuations. Currently, the utility of assessing individual patients' cortisol circadian rhythm during diagnosis and treatment of CS is not well characterized. In this review we will discuss how cortisol is measured in clinical practice and the potential benefit of measurement and normalization of the cortisol circadian rhythm.

#2

Prevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2026 Feb

Endogenous Cushing syndrome is associated with an intrinsic hypercoagulable state and an increased risk of venous thromboembolism (VTE). This study aimed to determine the prevalence and risk factors for VTE in a large cohort of patients with Cushing disease (CD). A retrospective study was conducted at a tertiary care center, including 408 patients diagnosed with CD. Clinical, laboratory, hormonal, imaging, and outcome data were analyzed and compared based on the occurrence of VTE events. A control group of 323 patients with clinically nonfunctioning pituitary adenomas, all macroadenomas, who underwent similar surgical procedures, was used for comparison. VTE events were observed in 35 patients with CD (8.6%) and in 1 patient from the nonfunctioning pituitary adenoma group (0.3%; P < .001). The slight majority of VTE events (54%) occurred in the preoperative period. Logistic regression analysis identified obesity, mood disorders, supraclavicular fossa fullness, leukopenia or leukocytosis, elevated cortisol levels (both serum and 24-hour urinary cortisol), and the presence of postoperative complications (such as infections, cerebrospinal fluid leak, and vasopressin deficiency) as significant risk factors for VTE. The findings of this study confirm a high prevalence of VTE events in patients with CD, irrespective of the surgical period. Risk factors associated with a higher likelihood of VTE include obesity, severity of hypercortisolism, and the occurrence of postoperative complications. In this patient population, thromboprophylaxis should be considered.

#3

Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.

The Journal of clinical endocrinology and metabolism2025 Nov 19

Osilodrostat's clinical development program mostly enrolled Cushing disease patients. Data in non-pituitary Cushing syndrome (CS) are limited. Evaluate osilodrostat effectiveness and safety in non-pituitary CS in real-world practice in France. Retrospective, observational study (LINC 7; NCT05633953). Data for patients who initiated osilodrostat under the French Autorisation Temporaire d'Utilisation scheme or, once approved, in routine clinical practice were extracted retrospectively for ≤36 months (2019-2022). Multicenter institutional practice. 103 adult non-pituitary CS patients: ectopic adrenocorticotropic hormone secretion (EAS), n=53; adrenocortical carcinoma (ACC), n=19; adrenal adenoma (AA), n=17; bilateral adrenal nodular disease (BND), n=14. 43 remained on osilodrostat throughout the observation period. Median (min-max) osilodrostat exposure and baseline dose: 177 days (1-1178), 5.0 mg/day (1-60). Proportion with mean urinary free cortisol (mUFC) ≤ upper limit of normal (ULN) at week (W) 12 (modified intention-to-treat [mITT] population: all enrolled patients with ≥12W follow-up, excluding patients without W12 mUFC for non-safety reasons). Osilodrostat was initiated and titrated based on investigator judgment. Cortisol decreased by W4, remaining stable thereafter. 23/52 patients (mITT; 44.2%, 95% CI 30.5-58.7) had mUFC ≤ULN at W12 (missing values input as non-responders). 45/52 had W12 mUFC available; proportion with mUFC ≤ULN by etiology: EAS, n=12/29 (41%); ACC, n=4/6; AA, n=1/3; BND, n=6/7. Most common (≥15%) TEAEs: adrenal insufficiency (28%) and hypokalemia (18%). 29 patients (EAS, n=24; ACC, n=5) died from AEs (n=1 assessed as osilodrostat related by investigator), mostly neoplasm progression (n=11). Osilodrostat is a suitable treatment for endogenous Cushing syndrome of various non-pituitary etiologies.

#4

Prolonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing's disease with eventual hypercortisolism relapse: Case Report and literature review.

Frontiers in medicine2025

Osilodrostat is a potent oral steroidogenesis inhibitor that is an effective medical therapy in the management of patients with endogenous Cushing syndrome. However, due to its high therapeutic potential, it is associated with a high risk of inducing adrenal insufficiency (AI). Recently, it has also been reported that patients may experience prolonged adrenal suppression during osilodrostat treatment that persists despite its withdrawal. In this paper, we present a male patient with persistent Cushing's disease (CD) who experienced several episodes of AI during long-term treatment with osilodrostat. Ultimately, due to the patient's very low dose of osilodrostat, it was decided to discontinue the therapy after 270 weeks in total. Following the cessation of osilodrostat, the patient commenced treatment with recombinant human growth hormone due to severe growth hormone deficiency, which revealed an underlying cortisol deficiency, likely caused by a prolonged adrenocortical blockage induced by osilodrostat, requiring the initiation of hydrocortisone replacement therapy. During and after the osilodrostat therapy, we additionally observed a low serum concentration of dehydroepiandrosterone sulfate (DHEA-S) despite elevated plasma adrenocorticotrophin. This finding suggested potential inhibition of adrenal steroidogenesis upstream of 11β-hydroxylase. A urine steroid profile performed 40 weeks after discontinuing osilodrostat showed reduced or borderline excretion of cortisol metabolites, as well as significantly decreased excretion of DHEA metabolites. Finally, 62 weeks after the last exposure to osilodrostat, the patient presented with clinical and biochemical features of relapse of hypercortisolemia, and osilodrostat was reintroduced. This case highlights the importance of close monitoring in patients treated with osilodrostat, as hypocortisolemia can arise suddenly and unexpectedly at any point during treatment, even in those on stable doses. Additionally, it indicates that osilodrostat has the potential to induce prolonged adrenal blockade, even after treatment has ceased. The unexpected persistence of adrenal suppression suggests unknown long-term effects of osilodrostat that require further investigation.

#5

Artri King induced Cushing syndrome in an 82-year-old man.

Dermatology online journal2025 Jun 15

An 82-year-old man with a history of hypertension, thyroid nodule, and parkinsonism on carbidopa/levodopa was referred for a sudden eruption of scattered purpuric macules. He noted fatigue, weakness, ankle swelling, abdominal fullness, headaches, lapses in memory, and dysphasia. On physical examination, he had thin and atrophied upper extremities and central obesity, as well as nonblanching red to purple macules on the lower abdomen and ecchymosis on bilateral arms. The patient denied the use of any corticosteroids. Lab workup showed an abnormally high post-dexamethasone cortisol level, which raised suspicion for Cushing syndrome. Further inquiry into the patient's medication and supplement history revealed that he was consuming Artri King, a supplement marketed for the treatment of joint pain and arthritis. Artri King can lead to numerous dermatological manifestations akin to endogenous Cushing syndrome such as thin skin, easy bruising, and purple striae. This case illustrates the potential risks of over-the-counter dietary supplements, which often circumvent the strict Food and Drug Administration regulations applied to prescription medications, posing significant health hazards to users. There is critical need for transparency and regulation of supplements.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC19 artigos no totalmostrando 55

2026

Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.

The Journal of clinical endocrinology and metabolism
2025

Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.

The Journal of clinical endocrinology and metabolism
2026

Prevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Prolonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing's disease with eventual hypercortisolism relapse: Case Report and literature review.

Frontiers in medicine
2025

Artri King induced Cushing syndrome in an 82-year-old man.

Dermatology online journal
2025

Advances in the medical management of hypercortisolism: current strategies, monitoring, and emerging therapies.

Current opinion in endocrinology, diabetes, and obesity
2025

Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A Review.

Diabetes
2025

Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study.

Journal of the Endocrine Society
2025

Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations.

Journal of the Endocrine Society
2025

Relationship Among Fragility Fractures and the Overall Cardiovascular Burden in Endogenous Cushing Syndrome.

Journal of the Endocrine Society
2025

Bone Mineral Density Improvement After Resolution of Endogenous Cushing Syndrome: A Systematic Review and Meta-Analysis.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Relacorilant or surgery improved hemostatic markers in Cushing syndrome.

Journal of endocrinological investigation
2024

Paediatric Cushing syndrome: a prospective, multisite, observational cohort study.

The Lancet. Child &amp; adolescent health
2023

ARMC5-negative primary bilateral macronodular adrenal hyperplasia.

BMJ case reports
2023

Cushing disease in pediatrics: an update.

Annals of pediatric endocrinology &amp; metabolism
2023

[Dynamics of NT-proBNP and ST2 levels as markers of heart failure in patients with endogenous Cushing syndrome (hypercortisolism)].

Terapevticheskii arkhiv
2022

Approach to the Patient: Diagnosis of Cushing Syndrome.

The Journal of clinical endocrinology and metabolism
2022

Ultra-high field 7 T MRI localizes regional brain volume recovery following corticotroph adenoma resection and hormonal remission in Cushing's disease: A case series.

Surgical neurology international
2023

A Two-in-One Tumor in the Adrenal: A Functional Adrenocortical Adenoma with Myelolipomatous Differentiation.

Fetal and pediatric pathology
2022

The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality.

The Journal of clinical endocrinology and metabolism
2022

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.

Pituitary
2022

Epidemiology of Male Hypogonadism.

Endocrinology and metabolism clinics of North America
2022

Inflammatory biomarkers in the evaluation of pediatric endogenous Cushing syndrome.

European journal of endocrinology
2021

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.

Frontiers in endocrinology
2021

Cushing Syndrome Associated Myopathy: It Is Time for a Change.

Endocrinology and metabolism (Seoul, Korea)
2021

Intratumoral steroid profiling of adrenal cortisol-producing adenomas by liquid chromatography- mass spectrometry.

The Journal of steroid biochemistry and molecular biology
2022

Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21.

The Journal of allergy and clinical immunology
2021

To determine the efficacy of bilateral inferior petrosal sinus sampling in differentiating Cushing disease from ectopic Cushing syndrome.

JPMA. The Journal of the Pakistan Medical Association
2020

Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations.

Clinical diabetes and endocrinology
2021

Adrenally Directed Medical Therapies for Cushing Syndrome.

The Journal of clinical endocrinology and metabolism
2021

Differences in outcomes of bilateral adrenalectomy in patients with ectopic ACTH producing tumor of known and unknown origin.

American journal of surgery
2020

Spinal Epidural Lipomatosis with Osteoporotic Vertebral Fractures Presenting as Acute Thoracic Myelopathy in a 33-Year-Old Man with Cushing Disease.

World neurosurgery
2020

Ectopic Cushing syndrome caused by a pancreatic neuroendocrine tumor: A case report.

Radiology case reports
2019

Pediatric Cushing Syndrome; an Overview.

Pediatric endocrinology reviews : PER
2019

68Ga-DOTATATE PET/CT of Ectopic Cushing Syndrome Due to Appendicular Carcinoid.

Clinical nuclear medicine
2019

Heat-Damaged Red Blood Cell Scintigraphy in Helping Interpretation of 68Ga-DOTATATE PET/CT.

Clinical nuclear medicine
2019

Optical Imaging Technology: A Useful Tool to Identify Remission in Cushing Disease After Surgery.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2018

Carney Syndrome Presented as a Pathological Spine Fracture in a 35-Year-Old Male.

The American journal of case reports
2018

Mini-review of hair cortisol concentration for evaluation of Cushing syndrome.

Expert review of endocrinology &amp; metabolism
2018

Diverticular Perforation: A Fatal Complication to Forestall in Cushing Syndrome.

The Journal of clinical endocrinology and metabolism
2018

Incidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2019

CHOROIDAL THICKENING AND PACHYCHOROID IN CUSHING SYNDROME: Correlation With Endogenous Cortisol Level.

Retina (Philadelphia, Pa.)
2017

Evaluation of Evidence of Adrenal Insufficiency in Trials of Normocortisolemic Patients Treated With Mifepristone.

Journal of the Endocrine Society
2017

Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers.

International journal of endocrinology
2017

Hypercortisolemia and Depressive-like Behaviors in a Rhesus Macaque (Macaca mulatta) Involved in Visual Research.

Comparative medicine
2017

Influence of age, gender and body mass index on late-night salivary cortisol in healthy adults.

Clinical chemistry and laboratory medicine
2017

Circadian Plasma Cortisol Measurements Reflect Severity of Hypercortisolemia in Children with Different Etiologies of Endogenous Cushing Syndrome.

Hormone research in paediatrics
2017

Cushing syndrome in a child due to pro-opiomelanocortin (POMC) secretion from a yolk sac tumor.

European journal of endocrinology
2016

Effects of Glucocorticoids on Bone: What we can Learn from Pediatric Endogenous Cushing's Syndrome.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2016

Diurnal Plasma Cortisol Measurements Utility in Differentiating Various Etiologies of Endogenous Cushing Syndrome.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2016

Diagnosis and Clinical Genetics of Cushing Syndrome in Pediatrics.

Endocrinology and metabolism clinics of North America
2016

Cases of Psychiatric Morbidity in Pediatric Patients After Remission of Cushing Syndrome.

Pediatrics
2016

[Serum Myokines Levels in Patients with Endogenous Cushing Syndrome and Acromegaly: Cross-Sectional Case−Control Study].

Vestnik Rossiiskoi akademii meditsinskikh nauk
2016

Kaposi sarcoma secondary to endogenous adrenocorticotropic hormone-dependent Cushing syndrome.

The British journal of dermatology
2015

ASSOCIATION BETWEEN MIFEPRISTONE DOSE, EFFICACY, AND TOLERABILITY IN PATIENTS WITH CUSHING SYNDROME.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Cushing endógena.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Cushing endógena

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
    The Journal of clinical endocrinology and metabolism· 2026· PMID 41830485mais citado
  2. Prevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists· 2026· PMID 41106685mais citado
  3. Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.
    The Journal of clinical endocrinology and metabolism· 2025· PMID 41260612mais citado
  4. Prolonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing's disease with eventual hypercortisolism relapse: Case Report and literature review.
    Frontiers in medicine· 2025· PMID 41030260mais citado
  5. Artri King induced Cushing syndrome in an 82-year-old man.
    Dermatology online journal· 2025· PMID 40991472mais citado
  6. "Glucocorticoids, Cushing syndrome and cellular senescence: a mechanistic link to metabolic ageing".
    Endocr Connect· 2026· PMID 41954322recente
  7. The Modern Presentation, Etiology, and Rate of Occurrence of Cushing Syndrome Differs when Compared to Prior Population-Based Studies.
    AACE Endocrinol Diabetes· 2026· PMID 41938295recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:641613(Orphanet)
  2. MONDO:0957431(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Cushing endógena
Compêndio · Raras BR

Síndrome Cushing endógena

ORPHA:641613 · MONDO:0957431
Ensaios
2 ativos
MedGen
UMLS
C5419158
EuropePMC
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades